Pomerantz Law Firm Investigates Potential Claims against Valneva SE Investors Amid Safety Concerns
On October 18, 2025, Pomerantz LLP, a well-known law firm in the domain of securities and class action litigation, announced that it is conducting an investigation on behalf of investors in Valneva SE, a company listed on NASDAQ under the ticker symbol VALN. The investigation focuses on potential claims or misconduct that may have jeopardized the interests of Valneva investors, particularly in light of alarming safety reports linked to one of its vaccines.
On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) made news when it reported ongoing investigations into five hospitalizations involving older adults who had received Valneva's chikungunya vaccine, IXCHIQ. The implications of this report were significant, resulting in a notable decline in Valneva's American Depositary Receipt (ADR) price, which plunged by $1.06—or 13.57%—in just four trading days, settling at $6.75 per ADR by February 28.
Further compounding the company’s troubles, on August 22, 2025, the U.S. Food and Drug Administration (FDA) announced the suspension of the marketing application for IXCHIQ, citing safety concerns as the primary reason. Following this critical announcement, Valneva's ADR price fell sharply again by $2.21 (or 18.99%), leading to a closing price of $9.43 on August 25.
The fallout from these events has placed Valneva in a precarious situation. Investors are encouraged to take notice of the ongoing investigation by Pomerantz LLP, which is recognized as a leader in handling corporate and securities litigation, particularly class action lawsuits. Founded by Abraham L. Pomerantz, the firm has a storied history in advocating for investors’ rights, recovering significant multimillion-dollar settlements on behalf of those victimized by securities fraud and corporate malpractice.
Pomerantz is inviting affected investors to reach out if they have suffered losses due to their association with Valneva. Legal experts at the firm are prepared to assess the situation for potential claims of securities fraud or other unlawful practices conducted by Valneva or its executives.
The commitment of Pomerantz Law Firm to provide rigorous representation in such matters aligns seamlessly with their longstanding tradition of fighting for the rights of investors. Their thorough consultations and investigations may help to uncover any omitted or misleading information related to the safety of Valneva’s products that may have influenced investor decisions.
It’s crucial for current and former investors of Valneva SE to stay informed of developments in this case as it unfolds. For inquiries, investors can reach out to Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980. The situation remains fluid and increasingly warrants the attention of all parties involved in Valneva’s financial landscape.
Overall, Valneva SE's recent challenges serve as a reminder of the intrinsic risks associated with biotech investments, particularly when it comes to the regulatory landscape surrounding public health and safety. As investigations proceed, the future of Valneva, along with its investor base, remains uncertain, leaving many to hope for clarity and resolution in the days ahead.
On February 25, 2025, the U.S. Centers for Disease Control and Prevention (CDC) made news when it reported ongoing investigations into five hospitalizations involving older adults who had received Valneva's chikungunya vaccine, IXCHIQ. The implications of this report were significant, resulting in a notable decline in Valneva's American Depositary Receipt (ADR) price, which plunged by $1.06—or 13.57%—in just four trading days, settling at $6.75 per ADR by February 28.
Further compounding the company’s troubles, on August 22, 2025, the U.S. Food and Drug Administration (FDA) announced the suspension of the marketing application for IXCHIQ, citing safety concerns as the primary reason. Following this critical announcement, Valneva's ADR price fell sharply again by $2.21 (or 18.99%), leading to a closing price of $9.43 on August 25.
The fallout from these events has placed Valneva in a precarious situation. Investors are encouraged to take notice of the ongoing investigation by Pomerantz LLP, which is recognized as a leader in handling corporate and securities litigation, particularly class action lawsuits. Founded by Abraham L. Pomerantz, the firm has a storied history in advocating for investors’ rights, recovering significant multimillion-dollar settlements on behalf of those victimized by securities fraud and corporate malpractice.
Pomerantz is inviting affected investors to reach out if they have suffered losses due to their association with Valneva. Legal experts at the firm are prepared to assess the situation for potential claims of securities fraud or other unlawful practices conducted by Valneva or its executives.
The commitment of Pomerantz Law Firm to provide rigorous representation in such matters aligns seamlessly with their longstanding tradition of fighting for the rights of investors. Their thorough consultations and investigations may help to uncover any omitted or misleading information related to the safety of Valneva’s products that may have influenced investor decisions.
It’s crucial for current and former investors of Valneva SE to stay informed of developments in this case as it unfolds. For inquiries, investors can reach out to Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980. The situation remains fluid and increasingly warrants the attention of all parties involved in Valneva’s financial landscape.
Overall, Valneva SE's recent challenges serve as a reminder of the intrinsic risks associated with biotech investments, particularly when it comes to the regulatory landscape surrounding public health and safety. As investigations proceed, the future of Valneva, along with its investor base, remains uncertain, leaving many to hope for clarity and resolution in the days ahead.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.